Matthew Decker, MD, PhD

Acute myeloid leukemia (AML) is hard to cure compared to other childhood leukemias and lymphomas. Current standard-of-care AML treatment is very toxic; childhood AML survivors often have side effects later in life from their treatment, including heart disease, infertility, and additional cancers. There is a pressing need for new AML treatments that are less toxic and more effective. Dr. Decker’s research is focused on developing novel inhibitors of a protein called N-Ras, one of the most common mutations in pediatric AML. Dr. Decker hopes by disrupting N-Ras function to sensitize AML to existing therapies and improve outcomes for patients. Dr. Decker received his MD and PhD from Columbia University, New York and his BS from Stanford University, Stanford.